Hidradenitis Suppurativa Clinical Trials

• Participants with a diagnosis of moderate to severe hidradenitis suppurativa (HS) for at least 6 months prior to Baseline

• Participants must have HS lesions present in at least 2 distinct anatomic areas (eg, left and right axilla; or left axilla and left inguinocrural fold), one of which must be Hurley Stage II or Hurley Stage III.

• Participant must have had an inadequate response to a trial of an oral antibiotic for treatment of HS, exhibited recurrence after discontinuation of antibiotics, demonstrated intolerance to antibiotics, or has a contraindication to oral antibiotics for treatment of their HS as assessed by the Investigator through participant interview and review of medical history.

• Participants must be either biologic-naive or biologic-experienced.

• Participant must have a total abscess and inflammatory nodule (AN) count of ≥5 at the Baseline visit.

• Participant must have a draining tunnel count of ≤20 at the Baseline visit.